Editas Medicine, Inc. (EDIT)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
EDIT Insider Trading Activity
EDIT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $253,868 | 1 | 8 |
Sells | $346,047 | 12 | 92 |
Related Transactions
| Hopfield Jessica | director | 1 | $253,868 | 0 | $0 | $253,868 |
| Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 0 | $0 | 4 | $40,162 | $-40,162 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $69,315 | $-69,315 |
| O'Neill Gilmore Neil | CEO | 0 | $0 | 4 | $104,136 | $-104,136 |
| Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $132,434 | $-132,434 |
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Insider Activity of Editas Medicine, Inc.
Over the last 12 months, insiders at Editas Medicine, Inc. have bought $253,868 and sold $346,047 worth of Editas Medicine, Inc. stock.
On average, over the past 5 years, insiders at Editas Medicine, Inc. have bought $837,319 and sold $1.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hopfield Jessica (director) — $253,868.
The last purchase of 45,000 shares for transaction amount of $253,868 was made by Hopfield Jessica (director) on 2024‑05‑13.
List of Insider Buy and Sell Transactions, Editas Medicine, Inc.
| 2025-03-04 | Sale | O'Neill Gilmore Neil | CEO | 16,632 0.0193% | $1.71 | $28,452 | -17.05% | |
| 2025-03-04 | Sale | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 4,109 0.0048% | $1.71 | $7,030 | -17.05% | |
| 2025-03-04 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 2,891 0.0034% | $1.71 | $4,946 | -17.05% | |
| 2024-12-03 | Sale | O'Neill Gilmore Neil | CEO | 1,618 0.0021% | $2.08 | $3,361 | -30.30% | |
| 2024-12-03 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 541 0.0007% | $2.08 | $1,124 | -30.30% | |
| 2024-09-04 | Sale | O'Neill Gilmore Neil | CEO | 1,555 0.0018% | $3.42 | $5,325 | -42.14% | |
| 2024-09-04 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 518 0.0006% | $3.42 | $1,774 | -42.14% | |
| 2024-07-25 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 11,886 0.0141% | $5.42 | $64,370 | -55.12% | |
| 2024-07-19 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 6,619 0.0084% | $5.21 | $34,456 | -46.82% | |
| 2024-06-04 | Sale | O'Neill Gilmore Neil | CEO | 12,191 0.0142% | $5.50 | $66,997 | -44.70% | |
| 2024-06-04 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 511 0.0006% | $5.50 | $2,808 | -44.70% | |
| 2024-05-20 | Sale | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 22,337 0.0276% | $5.61 | $125,404 | -41.85% | |
| 2024-05-13 | Hopfield Jessica | director | 45,000 0.0541% | $5.64 | $253,868 | -43.08% | ||
| 2024-03-05 | Sale | O'Neill Gilmore Neil | CEO | 77,824 0.0981% | $9.42 | $732,884 | -58.59% | |
| 2024-03-04 | Sale | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | 20,327 0.0237% | $9.42 | $191,425 | -61.64% | |
| 2023-12-05 | Sale | Eaton Bruce | EVP, CBO AND CTO | 103 0.0001% | $10.90 | $1,122 | -50.68% | |
| 2023-11-14 | Sale | Eaton Bruce | EVP, CBO AND CTO | 695 0.0008% | $8.21 | $5,706 | -34.45% | |
| 2023-11-07 | Sale | Eaton Bruce | EVP, CBO AND CTO | 139 0.0002% | $8.40 | $1,168 | -37.33% | |
| 2023-09-06 | Sale | Eaton Bruce | EVP, CBO AND CTO | 103 0.0001% | $8.82 | $908 | -22.92% | |
| 2023-08-11 | Sale | Eaton Bruce | EVP, CBO AND CTO | 702 0.0009% | $8.59 | $6,033 | -16.65% |
Insider Historical Profitability
| O'Neill Gilmore Neil | CEO | 295474 0.3561% | $387,070.94 | 0 | 6 | |
| Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 133354 0.1607% | $174,693.74 | 0 | 6 | |
| Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 112720 0.1358% | $147,663.20 | 0 | 2 | |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 70245 0.0847% | $92,020.95 | 0 | 2 | |
| Hopfield Jessica | director | 67700 0.0816% | $88,687.00 | 4 | 0 | <0.0001% |
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 3797144 4.5762% | $4.97M | 0 | 9 | |
| Bitterman Kevin | director | 2797144 3.371% | $3.66M | 0 | 10 | |
| VIKING GLOBAL INVESTORS LP | 2729808 3.2899% | $3.58M | 1 | 0 | ||
| VIKING GLOBAL PERFORMANCE LLC | 2729808 3.2899% | $3.58M | 1 | 0 | ||
| Bosley Katrine | President and CEO | 1204966 1.4522% | $1.58M | 0 | 26 | |
| Flynn James E | 10 percent owner | 954700 1.1506% | $1.25M | 1 | 0 | +20.25% |
| Glucksmann Alexandra | Chief Operating Officer | 117788 0.142% | $154,302.28 | 0 | 3 | |
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | 106610 0.1285% | $139,659.10 | 0 | 12 | |
| MULLEN JAMES C | CEO | 75898 0.0915% | $99,426.38 | 2 | 2 | <0.0001% |
| Eaton Bruce | EVP, CBO AND CTO | 74791 0.0901% | $97,976.21 | 0 | 23 | |
| Shearman Mark S | EVP, CHIEF SCIENTIFIC OFFICER | 65559 0.079% | $85,882.29 | 0 | 2 | |
| Collins Cynthia | CEO | 43760 0.0527% | $57,325.60 | 0 | 3 | |
| Nikolic Boris | director | 35000 0.0422% | $45,850.00 | 1 | 0 | +77.16% |
| Albright Charles | EVP/Chief Scientific Officer | 24907 0.03% | $32,628.17 | 0 | 14 | |
| Michaels Lisa Anne | EVP/Chief Medical Officer | 18432 0.0222% | $24,145.92 | 0 | 1 | |
| Cox Gerald Frank | Chief Medical Officer | 4000 0.0048% | $5,240.00 | 1 | 0 | +77.16% |
| STARR KEVIN P | 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Hack Andrew A. F. | Chief Financial Officer | 0 0% | $0 | 0 | 21 | |
| Myer Vickesh | Chief Technology Officer | 0 0% | $0 | 0 | 18 |
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $106.05M | |
$54,751,750 | 62 | -1.03% | $115.66M | |
$16,245,616 | 40 | 123.58% | $117.4M | |
$36,079,815 | 31 | 43.23% | $103.59M | |
$294,424,120 | 20 | 1.33% | $104.73M | |
$111,692,551 | 18 | 13.51% | $103.5M | |
$32,972,199 | 16 | -10.77% | $104.01M | |
$932,835 | 14 | -19.33% | $106.09M | |
$398,999,793 | 13 | -14.11% | $105.85M | |
$3,871,238 | 10 | -30.38% | $113.76M | |
Editas Medicine, Inc. (EDIT) | $6,593,243 | 8 | 12.72% | $108.7M |
$45,000,000 | 6 | -31.22% | $116.75M | |
$68,692,148 | 6 | -39.10% | $112.39M | |
$4,256,958 | 4 | 22.95% | $119.33M | |
$401,951 | 4 | 57.41% | $104.88M | |
$16,003,671 | 3 | 55.38% | $119.37M | |
$73,632,168 | 3 | -63.24% | $108.56M | |
$19,175,155 | 2 | 40.00% | $124.02M | |
$3,620 | 1 | 94.16% | $111.61M |
EDIT Institutional Investors: Active Positions
| Increased Positions | 101 | +35.82% | 11M | +20.1% |
| Decreased Positions | 117 | -41.49% | 15M | -26.21% |
| New Positions | 38 | New | 4M | New |
| Sold Out Positions | 59 | Sold Out | 10M | Sold Out |
| Total Postitions | 266 | -5.67% | 53M | -6.11% |
EDIT Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $10,670.00 | 8.81% | 7.31M | -716,636 | -8.93% | 2024-12-31 |
| Vanguard Group Inc | $9,962.00 | 8.22% | 6.82M | +143,392 | +2.15% | 2024-12-31 |
| Millennium Management Llc | $4,011.00 | 3.31% | 2.75M | -603,774 | -18.02% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $3,153.00 | 2.6% | 2.16M | -107,598 | -4.75% | 2024-12-31 |
| State Street Corp | $2,733.00 | 2.26% | 1.87M | -589,943 | -23.96% | 2024-12-31 |
| Geode Capital Management, Llc | $2,641.00 | 2.18% | 1.81M | -79,133 | -4.19% | 2024-12-31 |
| Goldman Sachs Group Inc | $2,608.00 | 2.15% | 1.79M | +619,011 | +53.03% | 2024-12-31 |
| Two Sigma Advisers, Lp | $2,419.00 | 2% | 1.66M | +528,000 | +46.77% | 2024-12-31 |
| Two Sigma Investments, Lp | $2,408.00 | 1.99% | 1.65M | +290,483 | +21.38% | 2024-12-31 |
| Morgan Stanley | $2,249.00 | 1.86% | 1.54M | +233,428 | +17.86% | 2024-12-31 |